Diabetes & Endocrinologyefruxiferminliver fibrosis
Efruxifermin Demonstrates Promising 96-Week Efficacy and Safety in Treating Metabolic Dysfunction-Associated Steatohepatitis: Insights from the Phase 2b HARMONY Trial
By MedXY|Oct 5, 2025
The HARMONY trial reveals that once-weekly efruxifermin significantly improves liver fibrosis without worsening MASH over 96 weeks, with a favorable safety profile supporting its phase 3 evaluation.
